Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2466
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report ; volume:21 ; number:1 ; day:28 ; month:1 ; year:2021 ; pages:1-4 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (28.1.2021), 1-4, 12.2021
- Creator
-
Duarte, Flávia Amaral
Rodrigues, Leonardo Brand
Paes, Flávia Rocha
Diniz, Paulo Henrique Costa
Lima, Helena Flávia Cuba de Almada
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-020-01390-6
- URN
-
urn:nbn:de:101:1-2021032120144895902638
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Duarte, Flávia Amaral
- Rodrigues, Leonardo Brand
- Paes, Flávia Rocha
- Diniz, Paulo Henrique Costa
- Lima, Helena Flávia Cuba de Almada
- SpringerLink (Online service)
Other Objects (12)
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFRmutation
Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”